Your browser doesn't support javascript.
loading
Initial Preserved Renal Function as a Predictor of Favorable Renal Response to Rituximab in Refractory or Relapsing Lupus Nephritis: A Single-center Cohort Study in Korea.
Choi, Su Jin; Ahn, Soo Min; Oh, Ji Seon; Hong, Seokchan; Lee, Chang-Keun; Yoo, Bin; Kim, Yong-Gil.
Afiliación
  • Choi SJ; Department of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Ahn SM; Department of Rheumatology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea.
  • Oh JS; Department of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Hong S; Department of Information Medicine, Asan Medical Center, Seoul, Korea.
  • Lee CK; Department of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Yoo B; Department of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Kim YG; Department of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
J Rheum Dis ; 29(1): 22-32, 2022 Jan 01.
Article en En | MEDLINE | ID: mdl-37476702
Objective: Previous studies investigating the beneficial effect of rituximab on lupus nephritis (LN) reported controversial results There have been few reports of renal response to rituximab according to renal function We investigated the efficacy of rituximab in refractory/relapsing LN and the role of renal function as a predictor of renal response. Methods: From 2016 to 2019, we retrospectively reviewed 22 patients with refractory/relapsing LN receiving rituximab Renal responses (complete and partial) at 6 and 12 months were compared between normal (glomerular filtration rate [GFR]≥90 mL/min/173 m2, n=11) and decreased (GFR<90 mL/min/173 m2, n=11) GFR groups Multivariate Cox regression analysis was used to assess predictors of renal response. Results: At baseline, the decreased GFR group had a higher urine proteinuria to creatinine ratio (p=0008) and proportion of refractory LN (p=0010) and previous cyclophosphamide therapy (p=0035) than the normal GFR group The overall renal response rate was 455% (10 patients) at 6 months and 545% (12 patients) at 12 months Renal response rates were higher in the normal GFR group (818% and 909% at 6 and 12 months, respectively) than in the decreased GFR group (91% and 182% at 6 and 12 months, respectively; p<0001) Normal GFR and anti-La were associated with renal response to rituximab, with hazard ratios of 9256 (p=0008) and 5478 (p=0041), respectively. Conclusion: Rituximab is an effective therapy for refractory/relapsing LN, particularly in patients with preserved renal function.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: J Rheum Dis Año: 2022 Tipo del documento: Article Pais de publicación: Corea del Sur
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: J Rheum Dis Año: 2022 Tipo del documento: Article Pais de publicación: Corea del Sur